28 / 31
Does Bevacizumab impact antiEGFR efficacy in
wtRAS
mCRC?
Derangère V et al. Oncotarget 2016
•
Retrospective study:
Francois Leclerc Cancer Center database
(Jan 2001 – Dec 2013)
•
Analysis:
•
PFS and OS were analyzed (Univariate & Multivariate Cox model)
•
In vitro studies WT KRAS/NRAS to evaluate VEGF-A impact on cetuximab-induced cell death
198 patients selected:
cetuximab/panitumumab
(2
nd
/3
rd
therapy)
128 patients
RAS wild type
76 patients (59%)
Received bevacizumab
(1
st
therapy)
52 patients (41%)
Did not receive bevacizumab
(1
st
therapy)